JG
AVIR icon

Jefferies Group’s Atea Pharmaceuticals AVIR Stock Holding History

Jefferies Group’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,500
Closed -$54.1K – 1546
2022
Q1 		$54.1K Hold
7,500
– – ﹤0.01% 1395
2021
Q4 		$67K Buy
+7,500
New +$117K ﹤0.01% 1509

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Jefferies Group's AVIR Position: Q2 2022 in Review

Jefferies Group sold out of Atea Pharmaceuticals (AVIR) in Q2 2022, closing a stake of 7,500 shares — an estimated $54.1K sold.

Jefferies Group first reported a position in AVIR in Q4 2021 and held it in 2 quarters. The position peaked at $67K in Q4 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q2 2022.

  • Jefferies Group reported no remaining Atea Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Jefferies Group sold 7,500 Atea Pharmaceuticals shares in Q2 2022, an estimated $54.1K.
  • Jefferies Group first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Jefferies Group's Atea Pharmaceuticals position peaked at $67K in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2022.

Based on Jefferies Group's 13F filing for Q2 2022, filed 15 Aug 2022.